BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September

Day

• 1
• 2
• 3
• 4
• 6
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 20
• 21
• 22
• 23
• 24
• 25

• Press Releases

  Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study

  September 14, 2026

   · 

  3 min read
• Press Releases

  Cytokinetics Announces Call for Proposals for Ninth Annual Communications Grant Program

  September 14, 2026

   · 

  5 min read
• Press Releases

  Bora Biologics Selected to Develop, Scale Up, and Supply RAPClot(TM) Protein Supporting Terumo’s Japan Launch of RAPClot Blood Collection Tubes

  September 14, 2026

   · 

  4 min read
• Press Releases

  AbelZeta Receives FDA IND Clearance for Phase 1b/2 Clinical Trial of C-CAR168 in Progressive Multiple Sclerosis

  September 14, 2026

   · 

  5 min read
• Press Releases

  MiniMed Files Form S-4 Registration Statement in Connection with Medtronic Exchange Offer Announcement

  September 14, 2026

   · 

  5 min read
• Press Releases

  Medtronic Launches Exchange Offer to Complete Separation of MiniMed Group, Inc.

  September 14, 2026

   · 

  9 min read
• Press Releases

  Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device

  September 14, 2026

   · 

  15 min read
• 

  Approvals

  Scholar Rock secures first FDA approval for muscle-targeting rare disease drug

  Scholar Rock’s spinal muscular atrophy drug, now to be called Isembyld, was originally rejected in September 2025, when the FDA cited compliance problems at a third-party manufacturer.

  September 14, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Breast cancer

  AstraZeneca’s newly approved cancer pill fails late-stage study, blocking path to bigger market

  SERENA-4 was assessing AstraZeneca’s Etcamah as a first-line option for certain patients with advanced breast cancer—a setting that could have meant a $2.9 billion opportunity for the drug.

  September 14, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Santa Ana Bio Announces First Subjects Dosed in Phase 1 Study of SAB01 to Treat Autoimmune Inflammatory Diseases

  September 14, 2026

   · 

  2 min read